Cargando…
Longitudinal Analysis of Real-World Performance of an Implantable Continuous Glucose Sensor over Multiple Sensor Insertion and Removal Cycles
The Eversense(®) Continuous Glucose Monitoring (CGM) System, with the first long-term, implantable glucose sensor, has been commercially available in Europe and South Africa since 2016 for adults with diabetes. The performance of the sensor over multiple, sequential 90- or 180-day cycles from either...
Autores principales: | Tweden, Katherine S., Deiss, Dorothee, Rastogi, Ravi, Addaguduru, Suresh, Kaufman, Francine R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196365/ https://www.ncbi.nlm.nih.gov/pubmed/31697182 http://dx.doi.org/10.1089/dia.2019.0342 |
Ejemplares similares
-
Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study
por: Deiss, Dorothee, et al.
Publicado: (2020) -
A Prospective Multicenter Evaluation of the Accuracy and Safety of an Implanted Continuous Glucose Sensor: The PRECISION Study
por: Christiansen, Mark P., et al.
Publicado: (2019) -
Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor
por: Christiansen, Mark P., et al.
Publicado: (2017) -
Continuous Glucose Sensor Survival and Accuracy Over 14 Consecutive Days
por: DeSalvo, Daniel J., et al.
Publicado: (2016) -
Clinical use of a 180‐day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes
por: Irace, Concetta, et al.
Publicado: (2020)